Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Caffeine (200 mg) Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

NCT01766050
View directory record Official record
Conditions
Transplant Rejection
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Belatacept
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 24, 2026, 3:23 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

NCT02760615
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Early Phase 1 Interventional Results available

Caffeine and Neurologic Recovery Following Surgery and General Anesthesia

NCT03577730
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Caffeine Citrate, Dextrose Water
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

NCT01462318
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Midazolam, Caffeine, S-warfarin, Vitamin K, Omeprazole, Dextromethorphan, BIIB019 (Daclizumab)
Drug · Other · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Centennial, Colorado • Washington D.C., District of Columbia • Lake Barrington, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue

NCT01944215
View directory record Official record
Conditions
Molecular Imaging
Interventions
Meal, Exercise, Sestamibi, Caffeine Tablet, External Heating
Dietary Supplement · Other · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 24, 2026, 3:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Short-term Effects of Caffeine and a Multi-ingredient Pre-workout on Exercise Performance

NCT07024940
View directory record Official record
Conditions
Coffee, Anthocyanins, Exercise Performance
Interventions
Ethiopian Coffee, Supplement, Water (Placebo)
Other · Dietary Supplement
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Changes in Metabolic Rate and Perceptual Indicators After Acute Ingestion of Paraxanthine

NCT05811923
View directory record Official record
Conditions
Metabolic Syndrome, Caffeine
Interventions
Venous Blood Collection, Resting Metabolic Rate Determination, Mood State, Visual Analog Scales
Other
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 24, 2026, 3:23 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Caffeine on Chess Performance and Cognitive Function in Professional Chess Players

NCT07641335
View directory record Official record
Conditions
Cognitive Performance, Attention, Reaction Time, Caffeine
Interventions
Caffeinated Coffee, Decaffeinated Coffee Placebo
Dietary Supplement
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

NCT05657613
View directory record Official record
Conditions
Drug Interactions
Interventions
CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

NCT02685462
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Atorvastatin, Simvastatin, Digoxin, Caffeine
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Results available

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

NCT02688088
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Drug Cocktail, Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Denver, Colorado • Indianapolis, Indiana • Fairway, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 24, 2026, 3:23 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Dietary Conditions on Drug Response

NCT04315961
View directory record Official record
Conditions
Healthy
Interventions
Blinded drug dose conditions
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

"The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women"

NCT02180048
View directory record Official record
Conditions
Overactive Bladder, Caffeine, Menopause
Interventions
400 mg of caffeine/day (Two 200mg pills/day), 200 mg of caffeine/day (One 200mg pill and one placebo pill), Two placebo pills/day
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
58 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

NCT02397382
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Midazolam, Warfarin, Omeprazole, Dextromethorphan, Caffeine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Anniston, Alabama • North Hollywood, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)

NCT00809471
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
placebo, avanafil
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

NCT00741468
View directory record Official record
Conditions
Drug Interactions
Interventions
Proellex, CYP1A2 probe, CYP2C9 probe, CYP2C19 probe, CYP2D6 probe, CYP3A4 probe
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

NCT06215430
View directory record Official record
Conditions
Healthy
Interventions
Caffeine Tablet, Omeprazole capsule, Warfarin tablet, Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Not applicable Interventional

Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans?

NCT00205166
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Cardiac SPECT imaging Rest and Stress, Caffeine
Procedure · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 28, 2012 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With a Potential Alzheimer's Disease Compound

NCT00726726
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan), BMS-708163, BMS-708163 + Cooperstown Cocktail
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2008 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Not applicable Interventional

Treatment of Low Metabolic Rate Following Bariatric Surgery

NCT01596907
View directory record Official record
Conditions
Morbid Obesity
Interventions
Ephedrine sulfate with caffeine, cellulose
Drug
Lead sponsor
Oregon Weight Loss Surgery, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Beaverton, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pre-Workout on Exercise Performance and Cognition

NCT02255201
View directory record Official record
Conditions
Healthy
Interventions
Master Performance Blend Dose 1, Master Performance Blend Dose 2, Performance Energy Blend, Energy Blend, Placebo
Dietary Supplement
Lead sponsor
Miami Research Associates
Network
Eligibility
18 Years to 40 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized Study to Examine the Ability of a Caffeine-Based Energy Drink to Impact Energy Expenditure, Fat Oxidation, Reaction Time, and Other Perceptual Indicators

NCT05998096
View directory record Official record
Conditions
Energy Expenditure, Cognition, Reaction Time
Interventions
Caffeine-Based Energy Drink, Placebo
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect and CYP1A2 Induction Study in Healthy Subjects

NCT02168205
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Pomalidomide, Caffeine, Tobacco
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
40 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 24, 2026, 3:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

NCT03675412
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
Caffeine tablet
Dietary Supplement
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 24, 2026, 3:23 PM EDT